Pharmacies, AGs Claim Sides On FDA's Generic Label Plan
By Michael Lipkin (March 12, 2014, 6:16 PM EDT) -- Dozens of state attorneys general and more than 20 pharmacies and trade groups squared off on opposing sides Wednesday over the U.S. Food and Drug Administration's controversial plan to let generic-drug makers independently change their warning labels.
In separate letters to the FDA, the attorneys general praised the proposed rule as an incentive for generics manufacturers to keep a close eye on their drugs, while the pharmacies argued the potential for differing warnings would confuse the market and eventually drive up prices.
The current rules prevent generic-drug makers from updating labels without prior FDA approval, something name-brand manufacturers are allowed to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!